teaser
Head and neck cancers respond well to erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium.
Erlotinib is an oral drug that can slow a tumour’s growth and spread by inhibiting specific growth receptors on the surface of the cancer cells.
Early detection of a patient’s response to epidermal growth factor receptor (EGFR) inhibitors, such as erlotinib, is critical to personalising head and neck cancer treatments.
In a first of its kind study in patients with head and neck cancer, researchers sought to determine how well tumours unaffected by other therapies respond to erlotinib, when the drug dose was adjusted according to the patient’s smoking status. It has been recently shown that smokers metabolize the drug faster than non-smokers.
Non-smokers received 150mg per day and smokers received 300mg per day for at least 14 days before surgery.
A fluorodeoxyglucose positron emission tomography (FDG-PET) scan and neck computed tomography (CT) was performed before treatment and at the end of erlotinib administration.
In addition, an early FDG-PET was performed after four to six days of treatment.
The results showed that erlotinib is effective as a first line of therapy when the dose is adjusted per smoking status, even when used for a limited duration.
Both smokers and non-smokers tolerated the dose of erlotinib and neither experienced serious adverse effects.
The study also showed that the FDG-PET scan taken early can show changes in the standard uptake value and predict a patient’s response to erlotinib.
“We hope our results will motivate clinicians to consider and investigate further the use of erlotinib in patients with head and neck cancer and adjust the dose for smoking status,” said lead author Mercedes Porosnicu, Assistant Professor of Internal Medicine at Wake Forest Baptist Medical Centre in America.
“We also hope that our study will help better select the patients expected to respond to erlotinib.”
Head and Neck Cancer Symposium
